arrow
N

Nicole D. Fleming

invalid
H指数:35
被引数:4,020

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The dynamic immune behavior of primary and metastatic ovarian carcinoma

原发性和转移性卵巢癌的动态免疫行为

2025-04-250
OA
A pioneering artificial intelligence tool to predict treatment outcomes in ovarian cancer via diagnostic laparoscopy

一种用于通过诊断性腹腔镜预测卵巢癌治疗结果的开拓性人工智能工具

2025-04-250
OA
The association of the chemotherapy response score and homologous recombination deficiency in patients undergoing interval tumor reductive surgery following neoadjuvant chemotherapy

化疗反应评分与同源重组缺陷在经过新辅助化疗后接受间隔肿瘤减灭术的患者中的关联

2025-04-190
PRE
Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial

帕博利珠单抗联合化疗在晚期卵巢癌一线治疗中的应用:一项II期临床试验的临床与转化研究结果

MED
IF11.8
2025-01-010
PRE
ASO Visual Abstract: Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent-Final Results from a Phase 2 Study
2024-05-090
PRE
The utility of surgical minimal residual disease after frontline treatment for prognostic and investigational opportunities in advanced ovarian cancer
2024-03-040
PRE
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer

tremelimumab和durvalumab联合与序贯治疗复发性铂类耐药卵巢癌的随机2期试验

CANCER
IF5.1
2023-11-274
PRE
In situ profiling reveals metabolic alterations in the tumor microenvironment of ovarian cancer after chemotherapy

原位分析揭示化疗后卵巢癌肿瘤微环境的代谢改变

2023-11-033
OAAI
Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer
2021-02-0175
OAAI